

Best of ASTRO 2016 Czech Republic

20. 3. 2017

Kongresové centrum Kunětická Hora Dříteč







09:30-10:10

Track 1 - Gastrointestinal

Renata Soumarova, Ass. Prof. (Oncology Centre Novy Jicin, Agel)

Abstract 1: (9755) The Initial Results for a Phase 3 Study of Short-term Versus Long-term Chemoradiation Therapy in Locally Advanced Rectal Cancer (STELLAR Trial)

Abstract 2: (12610) Phase 1 Study of Trametinib and Neoadjuvant Chemoradiation (CRT) in Locally Advanced Rectal Cancer (LARC) with KRAS, BRAF or NRAS Mutations

Abstract 3: (11923) Impact of Radiation Dose Escalation for Cervical Esophageal Cancer: A National Cancer Data Base (NCDB) Analysis

Abstract 4: (9812) A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared with Chemoradiation Therapy in Locally Advanced Gastroesophageal and Gastric Adenocarcinoma: Preliminary Results

Abstract 5: (11343) Patient-reported Outcomes (PROs) in NRG Oncology/RTOG 0436: A Phase 3 Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin and Radiation for Esophageal Cancer Treated without Surgery

Abstract 6: (8760) Prospective Randomized Phase 2 Study of Concurrent Chemoradiation Therapy (CCRT) Versus Chemotherapy Alone in Stage IV Esophageal Squamous Cell Carcinoma (ESCC)

Abstract 7: (11407) Combined Analysis of Two Prospective Trials of Individualized Adaptive Stereotactic Body Radiation Therapy for the Treatment of Hepatocellular Carcinoma (HCC) or Liver Metastases

Abstract 8: (12535) Protocol RAD 0902: A Pilot Study of Transarterial Chemoembolization Followed by Stereotactic Radiation Therapy for Locally Advanced Hepatocellular Carcinoma



10:10-10:50

Track 2 - Gynecological

Martina Kubecova, Ass. Prof. (Department of Oncology, University Hospital Kralovske Vinohrady, Prague)

Abstract 1: (11646) A Phase 3 Randomized Trial Comparing Patient-reported Toxicity and Quality of Life (QOL) During Pelvic Intensity Modulated Radiation Therapy as Compared to Conventional Radiation Therapy

Abstract 2: (8607) Phase 3 Randomized Trial of Comparing Chemoradiation Therapy Versus Radiation Therapy Alone in Lymph Node—negative Patients With Early-stage Cervical Cancer Following Radical Hysterectomy

Abstract 3: (10421) Nodal Failure After Chemoradiation and Magnetic Resonance Imaging Guided Adaptive BT in Cervical Cancer: A Subanalysis Within Embrace

Abstract 4: (7909) Phase 2 Multicenter Clinical Trial of Bone Marrow–sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin for Stage IB-IVA Cervical Cancer

Abstract 5: (10055) Computed Tomography Consensus Clinical Target Volume Contouring for Intensity Modulated Radiation Therapy in Intact Cervical Carcinoma

Abstract 6: (10547) National Cancer Data Base Analysis of Uterine Carcinosarcoma (UC): Improvement in Survival With the Use of Radiation Therapy

Abstract 7: (9670) Updated 4-Year Results for NRG Oncology/RTOG 0921: A Phase 2 Study of Postoperative Intensity Modulated Radiation Therapy With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer

Abstract 8: (10280) Implication of Adjuvant Radiation Therapy and Dose-Response Relationship for Margin-positive Vulvar Squamous Cell Carcinoma

Abstract 9: (11633) Impact of Cumulative Radiation Doses to Vagina on Late Toxicity and Sexual Quality of Life in Patients Treated With Postoperative Adjuvant Radiation Therapy for Cervical Cancer



11:00-11:40

Track 3 - Genitourinary

Karel Odrazka, Prof. (Oncology Centre Multiscan, Pardubice)

Abstract 1: (11006) Initial Report of NRG Oncology/ RTOG 0232: A Phase 3 Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate-risk Prostatic Carcinoma

Abstract 2: (9839) NRG Oncology/RTOG 0415, Phase 3 Noninferiority Study Comparing Two Fractionation Schedules in Patients with Low-risk Prostate Cancer: Prostate-specific Quality of Life Results

Abstract 3: (8550) Randomized Trial of Hypofractionated Dose-escalated Intensity Modulated Radiation Therapy Versus Conventionally Fractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer

Abstract 4: (12762) Five-year Outcomes from a Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-risk Prostate Cancer

Abstract 5: (7936) Long-term Androgen Deprivation, with or without Radiation Therapy, in Locally Advanced Prostate Cancer: Results from a Phase 3 Randomized Study After 7.3 Years Median Follow-up

Abstract 6: (8782) Androgen Deprivation and High-dose Radiation Therapy in Prostate Cancer: Report on Late Toxicity from DART 01/05 Randomized Phase III Trial

Abstract 7: (10807) Staging of Biochemically Relapsing Prostate Cancer Using the Positron Emission Tomography Tracer Fluciclovine F18

Abstract 8: (10451) Prostate Cancer-specific Mortality and Survival Outcomes for Salvage Radiation Therapy After Radical Prostatectomy



11:40-12:20

Track 4 - Oropharyngeal Guideline and APBI Consensus Update Martin Dolezel, Ass. Prof. (Oncology Centre Multiscan, Pardubice)

Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: An ASTRO Evidence-Based Clinical Practice Guideline

- 1. When is it appropriate to add systemic therapy to radiotherapy in the treatment of intact oropharyngeal squamous cell carcinoma (OPSCC)?
- 2. When is it appropriate to deliver post-operative radiotherapy with and without systemic therapy following primary surgery of OPSCC?
- 3. When is it appropriate to use induction chemotherapy in the treatment of OPSCC?
- 4. What are the appropriate dose, fractionation and volume regimens with and without chemotherapy in the treatment of OPSCC?

Accelerated Partial Breast Irradiation (APBI): An Update of an ASTRO Evidence-Based Consensus Statement

- 1. Lowering the suitability age to 50 instead of 60.
- 2. Adding low risk ductal carcinoma in situ (DCIS) to the suitable category.
- 3. Providing novel guidance to ASTRO membership on appropriate adoption of intraoperative radiation therapy (IORT) into clinical practice.



12:20-13:00

Track 5 - Breast

Jiri Petera, Prof. (Department of Oncology, Faculty Hospital Hr. Kralove)

Abstract 1: (8537) Radiation Boost for Ductal Carcinoma In Situ After Whole-breast Radiation Therapy (WBRT) Improves Local Control: Analysis From 10 Pooled Academic Institutions

Abstract 2: (10880) Efficacy of Mometasone Furoate in the Reduction of Moderate/Severe Radiation Dermatitis in Breast Cancer Patients Following Mastectomy

Abstract 3: (9294) Longitudinal Analysis of Patient-reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-breast Irradiation

Abstract 4: (11056) The Effect of Breast Irradiation on Cardiac Disease in Women Enrolled on BCIRG-001 at 10-Year Follow-up

Abstract 5: (12708) Regional Patterns of Breast Cancer Failure After Definitive Therapy: A Large, Single-institution Analysis

Abstract 6: (10934) The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients with Node-positive Breast Cancer Treated on SWOG S8814

Abstract 7: (11657) CD47 as a Target for Immune-radiation Therapy for HER2-Expressing Breast Cancer Cells

Abstract 8: (10231) Ten-year Results of the Breast Intensity Modulated Radiation Therapy (IMRT) Randomized Controlled Trial



14:00-14:40

Track 6 - Head and Neck

Milan Vosmik, PhD (Department of Oncology, Faculty Hospital Hr. Kralove)

Abstract 1: (10719) Concurrent Chemoradiation Therapy Versus Acceleration of Radiation Therapy with or without Concurrent Chemotherapy in Locally Advanced Head and Neck Carcinoma (GORTEC 99-02): Seven-year Survival Data from a Phase 3 Randomized Trial and Prognostic Factors

Abstract 2: (11726) Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy in Head and Neck Squamous Cell Carcinoma: A Pooled Analysis of NRG Oncology/ RTOG 0129 and 0522

Abstract 3: (7954) Radiation Therapy Variation in the Randomized Phase 3 Positron Emission Tomography Neck Study

Abstract 4: (11494) Multi-institution Analysis of Intensity Modulated Radiation Therapy-based Reirradiation for Head and Neck Cancer: Prognostic Factors and Recursive Partitioning Analysis for Overall Survival

Abstract 5: (11384) Optimal Treatment Selection of Stereotactic Body Radiation Therapy and Intensity Modulated Radiation Therapy for Reirradiation of Head and Neck Cancer: A Multi-institution Comparison

Abstract 6: (11896) Multi-institution Analysis of Intensity Modulated Radiation Therapy-based Reirradiation for Head and Neck Cancer: Improved Risk-benefit Profile in the Modern Era

Abstract 7: (11685) Phase 2 Trial of Induction Chemotherapy Followed by Attenuated Chemoradiation Therapy for Human Papillomavirus-positive Locally Advanced Squamous Cell Carcinoma of the Oropharynx

Abstract 8: (12761) Cetuximab-Based Bioradiation Therapy Versus Cisplatin-based Chemoradiation Therapy in the Definitive Treatment of Locally Advanced Oropharyngeal Squamous Cell Carcinoma



14:40-15:20

Track 7 - Lung

David Feltl, Ass. Prof. (Department of Oncology, Faculty Hospital Ostrava)

Abstract 1: (8415) Efficacy and Toxicity Analysis of NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Non-small Cell Lung Cancer (NSCLC)

Abstract 2: (9471) A Phase 2 Randomized Study of two Stereotactic Body Radiation Therapy (SBRT) Regimens for Medically Inoperable Patients with Node-negative, Peripheral Non-small Cell Lung Cancer

Abstract 3: (9460) Impact of Incidental Cardiac Radiation on Cardiopulmonary Toxicity and Survival for Locally Advanced Non-small Cell Lung Cancer: Reanalysis of NRG Oncology/RTOG 0617 with Centrally Contoured Cardiac Structures

Abstract 4: (9437) Safety of Dose Escalation by Simultaneous Integrated Boosting Radiation Dose in Unresectable Stage III Non-small Cell Lung Cancer

Abstract 5: (12343) Radiation Dose to the Thoracic Vertebral Bodies is Associated with Acute Hematologic Toxicity in Patients Receiving Concurrent Chemoradiation for Lung Cancer

Abstract 6: (8088) Identifying Patients with Extensive-stage Small Cell Lung Cancer (ES-SCLC) Most Likely to Benefit from Intensive Radiation Therapy

Abstract 7: (10285) The Differential Impact of Postoperative Radiation Therapy for Completely Resected Stage IIIA(N2) Non-small Cell Lung Cancer: Based on the Risk Prediction Model for Locoregional Recurrence

Abstract 8: (9088) Role of Surveillance Imaging Versus Symptoms and Signs in Detection of Recurrence of Non-small Cell Lung Cancer After Curative Intent Therapy



15:30-16:10

Track 8 - Central Nervous System

Pavel Slampa, Prof., Tomas Kazda, Dr (Department of Radiation Oncology, MMCI, Brno)

Abstract 1: (11991) Deferring Radiation Therapy for Brain Metastases in Patients with EGFR-mutant Non-small Cell Lung Cancer: A Multi-institutional Analysis

Abstract 2: (9559) Treatment of Cerebral Radiation Necrosis with Nerve Growth Factor—A Prospective, Randomized, Controlled Phase 2 Study

Abstract 3: (8991) Omission of Radiation Therapy for Low-grade Gliomas: Molecular and Radiographic Correlates of Treatment Response and Disease Progression on a Phase 2 Clinical Trial of Adjuvant Temozolomide

Abstract 4: (11889) Hippocampal Dosimetry Predicts for Cancer-related Cognitive Impairment in Patients Treated With Cranial Radiation Therapy: Dosimetric Results of a Prospective Clinical Trial

Abstract 5: (9336) Postoperative Stereotactic Radiosurgery Versus Observation for Completely Resected Brain Metastases: Results of a Prospective Randomized Study

Abstract 6: (11381) Mibefradil Dihydrochoride with Hypofractionated Radiation for Recurrent Glioblastoma: Preliminary Results of a Phase 1 Dose Expansion Trial

Abstract 7: (12187) Multi-institutional Competing Risks Analysis Predicting Distant Brain Failure and Salvage Patterns After Upfront Radiosurgery without Whole-Brain Radiation Therapy for Brain Metastasis

Abstract 8: (8673) Does Whole-brain Radiation Therapy for Oligometastatic Brain Metastases Translate into a Survival Benefit for Patients with a Limited Competing Risk from Extracranial Disease? A Secondary Analysis of EORTC 22952-26001



16:10-16:50

Track 9 - Physics

Petr Paluska, PhD (Department of Oncology, Faculty Hospital Hr. Kralove)

Abstract 1: (11670) Reinforcement Learning Strategies for Decision Making in Knowledge-based Adaptive Radiation Therapy: Application in Liver Cancer

Abstract 2: (8129) Selection of FDG Positron Emission Tomography-based Bioparametric Matrixes for Tumor Dose Response Mapping and Adaptive Dose Painting by Number

Abstract 3: (11039) Apparent Diffusion Coefficients (ADCs) in Diffusion-weighted 3.0 Tesla MR Imaging is Useful in Predicting Therapeutic Response to Concurrent Chemoradiation Therapy in Patients with Uterine Cervical Cancer: A Prospective Study

Abstract 4: (10095) First Clinical Implementation of Electromagnetic Transponder-guided MLC Tracking for Lung Stereotactic Ablative Radiation Therapy

Abstract 5: (9073) Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy (SABR) for Lung Cancer: Physician Performance Versus Radiomic Assessment



Contact: bestof@multiscan.cz, dolezelm@email.cz

Doc. MUDr. Martin Doležel, Ph.D. KOC Pardubického kraje, Kyjevská 44, 532 03 Pardubice www.multiscan.cz

Golf & Spa Kunětická Hora Dříteč 155, 533 05 GPS: 50°6'41.669"N, 15°49'9.128"E http://www.gckh.cz/kongresove-centrum.php